Abcam plc: Annual Report, Impact Report and Notice of AGM
November 03 2020 - 8:34AM
Abcam plc (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply
of life science research tools, announces that, following release
on 14 September 2020 of its final results for the year ended 30
June 2020, the Abcam plc Annual Report and Accounts 2020
(the “Annual Report”) have been published today and are
available on the Abcam plc website at www.abcamplc.com.
A copy of the Annual Report has been submitted
to the National Storage Mechanism and will shortly be available for
inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The Annual Report will also be posted today,
together with the Notice of Annual General Meeting, to those
shareholders that have elected to receive paper
communications. Shareholders that have not elected to receive
paper communications will be notified of the availability of these
documents on Abcam plc website, www.abcamplc.com.
2020 Impact Report
Reinforcing its commitment to long-term
sustainability, Abcam will also release its first dedicated Impact
Report on 9 November 2020. The report highlights the Group’s
approach to generating positive impact and creating sustainable
value. The report and further sustainability disclosures will be
published at www.abcamplc.com/sustainability/.
For further information, please contact:
Abcam |
+ 44 (0) 1223 696 000 |
Marc
Perkins, Company Secretary James Staveley, Vice President, Investor
Relations |
|
Numis – Nominated Advisor & Joint Corporate
Broker |
+ 44 (0) 20
7260 1000 |
Garry Levin
/ Duncan Monteith / Huw Jeremy |
|
About Abcam plc
As an innovator in reagents and tools, Abcam's
purpose is to serve life science researchers globally to achieve
their mission, faster. Providing the research and clinical
communities with tools and scientific support, the Company offers
highly validated antibodies and assays to address important targets
in critical biological pathways.
Already a pioneer in data sharing and ecommerce
in the life sciences, Abcam's ambition is to be the most
influential company in life sciences by helping advance global
understanding of biology and causes of disease, which, in turn,
will drive new treatments and improved health.
In the fiscal year ended 30 June 2020, Abcam’s
worldwide customer base consisted of approximately 750,000 life
science researchers. By actively listening to and collaborating
with these researchers, the Company continuously advances its
portfolio to address their needs. A transparent programme of
customer reviews and datasheets, combined with an industry-leading
validation initiative, gives researchers increased confidence in
their results.
Founded in 1998 and headquartered in Cambridge,
UK, the Company has served customers in more than 130 countries.
Abcam’s ordinary shares were admitted to trading on AIM in 2005
(AIM: ABC) and its American Depositary Shares began trading on the
Nasdaq Global Market in October 2020 (Nasdaq: ABCM).
Please visit www.abcam.com or
www.abcamplc.com to find out more.
AmerisourceBergen (NYSE:ABC)
Historical Stock Chart
From Aug 2024 to Sep 2024
AmerisourceBergen (NYSE:ABC)
Historical Stock Chart
From Sep 2023 to Sep 2024